Pub Date : 2026-01-01DOI: 10.1016/j.gastrohep.2025.502528
Francesc Casellas , Ana Gutiérrez-Casbas , Cristina Rodríguez , Javier P. Gisbert , Sabino Riestra , Claudia Herrera de Guise , Isabel Vera-Mendoza , Pilar Martínez-Montiel , Sónia Bernardo , Isabel Medeiros , Jesús Aparicio , Ignacio Tagarro , Teresa Letosa-Abián , Carmen Montoto , Fernando Muñoz
Objective
Real-world evidence (RWE) on vedolizumab (VDZ), an anti-lymphocyte trafficking treatment that selectively targets the α4β7/MAdCAM-1 interaction on the gut, is mostly limited to patients who are repeatedly refractory to anti-tumor necrosis factor-alpha (anti-TNF-α), and other treatments. The EVOLVE-IBERIA study assessed VDZ or anti-TNF-α as first- or second-line biologic treatment, in patients with Crohn's disease or ulcerative colitis (UC); here, we present the outcomes in patients with UC.
Patients and methods
Medical records were retrospectively reviewed from 25 hospitals in Spain and Portugal. Eligible patients with UC were aged ≥18 years and had received treatment with first- or second-line VDZ or anti-TNF-α. Objectives were to evaluate clinical effectiveness, safety, and treatment patterns of VDZ and anti-TNF-α, and to characterize healthcare resource utilization. Baseline covariates were balanced in both cohorts by means of propensity scores, using the inverse probability of treatment weighting (PS-IPTW) method.
Results
A total of 199 patients with UC were included (median follow-up: 24.0 months). At Week 52, clinical response rates were 75.6% and 73.2% (p = 0.72) and clinical remission rates were 56.6% and 62.0% (p = 0.49), in the VDZ cohort and anti-TNF-α cohort, respectively. Treatment-related adverse event rates per 100 patient-years were 0.23 in the VDZ cohort and 1.1 in the anti-TNF-α cohort (p = 0.037).
Conclusion
The similar long-term effectiveness and lower incidence of adverse events of VDZ compared with anti-TNF-α in the real-world setting, confirm the favorable benefit:risk ratio of VDZ as first- or second-line biologic treatment for UC.
{"title":"EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumor necrosis factor-α as first- or second-line biologic treatment among patients with ulcerative colitis","authors":"Francesc Casellas , Ana Gutiérrez-Casbas , Cristina Rodríguez , Javier P. Gisbert , Sabino Riestra , Claudia Herrera de Guise , Isabel Vera-Mendoza , Pilar Martínez-Montiel , Sónia Bernardo , Isabel Medeiros , Jesús Aparicio , Ignacio Tagarro , Teresa Letosa-Abián , Carmen Montoto , Fernando Muñoz","doi":"10.1016/j.gastrohep.2025.502528","DOIUrl":"10.1016/j.gastrohep.2025.502528","url":null,"abstract":"<div><h3>Objective</h3><div>Real-world evidence (RWE) on vedolizumab (VDZ), an anti-lymphocyte trafficking treatment that selectively targets the α4β7/MAdCAM-1 interaction on the gut, is mostly limited to patients who are repeatedly refractory to anti-tumor necrosis factor-alpha (anti-TNF-α), and other treatments. The EVOLVE-IBERIA study assessed VDZ or anti-TNF-α as first- or second-line biologic treatment, in patients with Crohn's disease or ulcerative colitis (UC); here, we present the outcomes in patients with UC.</div></div><div><h3>Patients and methods</h3><div>Medical records were retrospectively reviewed from 25 hospitals in Spain and Portugal. Eligible patients with UC were aged ≥18 years and had received treatment with first- or second-line VDZ or anti-TNF-α. Objectives were to evaluate clinical effectiveness, safety, and treatment patterns of VDZ and anti-TNF-α, and to characterize healthcare resource utilization. Baseline covariates were balanced in both cohorts by means of propensity scores, using the inverse probability of treatment weighting (PS-IPTW) method.</div></div><div><h3>Results</h3><div>A total of 199 patients with UC were included (median follow-up: 24.0 months). At Week 52, clinical response rates were 75.6% and 73.2% (<em>p</em> <!-->=<!--> <!-->0.72) and clinical remission rates were 56.6% and 62.0% (<em>p</em> <!-->=<!--> <!-->0.49), in the VDZ cohort and anti-TNF-α cohort, respectively. Treatment-related adverse event rates per 100 patient-years were 0.23 in the VDZ cohort and 1.1 in the anti-TNF-α cohort (<em>p</em> <!-->=<!--> <!-->0.037).</div></div><div><h3>Conclusion</h3><div>The similar long-term effectiveness and lower incidence of adverse events of VDZ compared with anti-TNF-α in the real-world setting, confirm the favorable benefit:risk ratio of VDZ as first- or second-line biologic treatment for UC.</div></div>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"49 1","pages":"Article 502528"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.gastrohep.2025.502560
Mónica Egea Sancho , José Ignacio Ramírez-Manent , Pedro Juan Tárraga López , Irene Coll Campayo , María Teófila Vicente-Herrero , Ángel Arturo López-González
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern, particularly among individuals with obesity. While metabolic and behavioral risk factors have been well described, the role of psychosocial determinants, such as weight stigma, remains underexplored.
Objectives
To assess the association between sociodemographic variables, healthy lifestyle behaviors, and internalized weight stigma with MASLD risk in a large cohort of obese workers across Spain.
Patients and methods
This cross-sectional study analyzed data from 26,816 obese employees who underwent occupational health screenings between January 2021 and December 2024. MASLD risk was assessed using three validated indices: the Fatty Liver Index (FLI), Hepatic Steatosis Index (HSI), and Lipid Accumulation Product (LAP). Sociodemographic characteristics, adherence to the Mediterranean diet, physical activity, smoking status, and weight stigma (assessed by the Weight Bias Internalization Scale) were evaluated. Multivariable logistic regression models were used to estimate associations.
Results
Weight stigma was significantly associated with higher risk of MASLD across all three indices, independent of age, sex, social class, and health behaviors. Participants with internalized weight stigma were 1.6–2.3 times more likely to present with high-risk scores. Sociodemographic disparities and unhealthy lifestyle factors also contributed to elevated MASLD risk.
Conclusions
Beyond metabolic and behavioral determinants, internalized weight stigma emerges as a strong independent factor associated with MASLD risk. These findings underscore the importance of incorporating psychosocial components into liver disease prevention strategies in occupational settings.
{"title":"Associations of sociodemographic factors, healthy habits, and weight stigma with non-alcoholic fatty liver disease risk in obese workers: Findings from a large occupational cohort","authors":"Mónica Egea Sancho , José Ignacio Ramírez-Manent , Pedro Juan Tárraga López , Irene Coll Campayo , María Teófila Vicente-Herrero , Ángel Arturo López-González","doi":"10.1016/j.gastrohep.2025.502560","DOIUrl":"10.1016/j.gastrohep.2025.502560","url":null,"abstract":"<div><h3>Background</h3><div>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern, particularly among individuals with obesity. While metabolic and behavioral risk factors have been well described, the role of psychosocial determinants, such as weight stigma, remains underexplored.</div></div><div><h3>Objectives</h3><div>To assess the association between sociodemographic variables, healthy lifestyle behaviors, and internalized weight stigma with MASLD risk in a large cohort of obese workers across Spain.</div></div><div><h3>Patients and methods</h3><div>This cross-sectional study analyzed data from 26,816 obese employees who underwent occupational health screenings between January 2021 and December 2024. MASLD risk was assessed using three validated indices: the Fatty Liver Index (FLI), Hepatic Steatosis Index (HSI), and Lipid Accumulation Product (LAP). Sociodemographic characteristics, adherence to the Mediterranean diet, physical activity, smoking status, and weight stigma (assessed by the Weight Bias Internalization Scale) were evaluated. Multivariable logistic regression models were used to estimate associations.</div></div><div><h3>Results</h3><div>Weight stigma was significantly associated with higher risk of MASLD across all three indices, independent of age, sex, social class, and health behaviors. Participants with internalized weight stigma were 1.6–2.3<!--> <!-->times more likely to present with high-risk scores. Sociodemographic disparities and unhealthy lifestyle factors also contributed to elevated MASLD risk.</div></div><div><h3>Conclusions</h3><div>Beyond metabolic and behavioral determinants, internalized weight stigma emerges as a strong independent factor associated with MASLD risk. These findings underscore the importance of incorporating psychosocial components into liver disease prevention strategies in occupational settings.</div></div>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"49 1","pages":"Article 502560"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.gastrohep.2025.502535
Clara Usón Peirón , Julia del Rio Izquierdo , Anna Baiges , Andrés Conthe
{"title":"Bridging the gap: The need for a standardized referral pathway for urgent TIPS placement in portal-hypertension related bleeding (“Code TIPS”)","authors":"Clara Usón Peirón , Julia del Rio Izquierdo , Anna Baiges , Andrés Conthe","doi":"10.1016/j.gastrohep.2025.502535","DOIUrl":"10.1016/j.gastrohep.2025.502535","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"49 1","pages":"Article 502535"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144803961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.gastrohep.2025.502558
Marta Teller , Antonio Giordano , Carlos González-Muñoza , Jordi Gordillo , Federico Bertoletti , Fernando Sánchez-Reus , Esther Garcia-Planella
Objective
Chlamydia trachomatis is a prevalent cause of infectious proctitis, often misdiagnosed as cancer or inflammatory bowel disease (IBD). This study aims to describe the main clinical symptoms, together with endoscopic and histopathological characteristics of C. trachomatis proctitis in the general population.
Patients and methods
A retrospective observational study was conducted at a single institution, identifying all cases of proctitis due to C. trachomatis infection, detected by real-time PCR in rectal biopsy or anal smear, with endoscopic assessment.
Results
A total of 28 male patients were included (median age 37, IQR 31–48). Among them, 20 patients reported having sex with males. Concomitant infections included HIV (n = 10), Neisseria gonorrhoea (n = 4), and Treponema pallidum (n = 2). A history of sexually transmitted diseases was reported by 18 patients (64%). The main clinical symptoms were rectal bleeding (79%) and diarrhoea (43%). The main endoscopic findings were rectal erythema (71%) and ulcers (57%), with rectal (89%) and sigmoid inflammation (11%). In 5 cases (18%), a single isolated deep rectal ulcer was the only finding. In 16 cases (57.1%), neoplasia, IBD or fissure was suspected according to endoscopy. Histological findings included mixed inflammatory infiltrate of lamina propria (95%), cryptitis (54%), and crypt abscesses (32%).
Conclusions
Endoscopically detected C. trachomatis proctitis in men presents with worrisome symptoms and nonspecific rectal ulcers, with chronic inflammation histology. This generates doubts about differential diagnosis with IBD and rectal cancer.
{"title":"Clinical, endoscopic and histological characteristics of Chlamydia trachomatis proctitis in males","authors":"Marta Teller , Antonio Giordano , Carlos González-Muñoza , Jordi Gordillo , Federico Bertoletti , Fernando Sánchez-Reus , Esther Garcia-Planella","doi":"10.1016/j.gastrohep.2025.502558","DOIUrl":"10.1016/j.gastrohep.2025.502558","url":null,"abstract":"<div><h3>Objective</h3><div><em>Chlamydia trachomatis</em> is a prevalent cause of infectious proctitis, often misdiagnosed as cancer or inflammatory bowel disease (IBD). This study aims to describe the main clinical symptoms, together with endoscopic and histopathological characteristics of <em>C. trachomatis</em> proctitis in the general population.</div></div><div><h3>Patients and methods</h3><div>A retrospective observational study was conducted at a single institution, identifying all cases of proctitis due to <em>C. trachomatis</em> infection, detected by real-time PCR in rectal biopsy or anal smear, with endoscopic assessment.</div></div><div><h3>Results</h3><div>A total of 28 male patients were included (median age 37, IQR 31–48). Among them, 20 patients reported having sex with males. Concomitant infections included HIV (<em>n</em> <!-->=<!--> <!-->10), <em>Neisseria gonorrhoea</em> (<em>n</em> <!-->=<!--> <!-->4), and <em>Treponema pallidum</em> (n<!--> <!-->=<!--> <!-->2). A history of sexually transmitted diseases was reported by 18 patients (64%). The main clinical symptoms were rectal bleeding (79%) and diarrhoea (43%). The main endoscopic findings were rectal erythema (71%) and ulcers (57%), with rectal (89%) and sigmoid inflammation (11%). In 5 cases (18%), a single isolated deep rectal ulcer was the only finding. In 16 cases (57.1%), neoplasia, IBD or fissure was suspected according to endoscopy. Histological findings included mixed inflammatory infiltrate of lamina propria (95%), cryptitis (54%), and crypt abscesses (32%).</div></div><div><h3>Conclusions</h3><div>Endoscopically detected <em>C. trachomatis</em> proctitis in men presents with worrisome symptoms and nonspecific rectal ulcers, with chronic inflammation histology. This generates doubts about differential diagnosis with IBD and rectal cancer.</div></div>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"49 1","pages":"Article 502558"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The incidence and prevalence of inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are increasing across Latin America. IBD has an important impact on patients’ quality of life and is associated with significant healthcare resource utilization (HCRU). This study aimed to describe the more recent epidemiological characteristics and HCRU patterns of IBD in Colombia.
Methods
Retrospective study using real-world data from the national claims database SISPRO (Sistema de Información para la Protección Social) between 2017 and 2021. The data considered were sociodemographic (sex and age), epidemiological (incidence, prevalence, and mortality), and HCRU data.
Results
We identified 54,961 cases of prevalent ulcerative colitis (UC) and 13,136 cases of Crohn's disease (CD). Between 2017 and 2019, the incidence rates for UC increased from 3.82 to 5.18 per 100,000 individuals, while the incidence for CD rose from 0.48 to 0.83 per 100,000. The prevalence of these conditions reached its highest point in 2019, with UC at 48.65 and CD at 15.41 per 100,000 population. Mortality data indicated 259 deaths registered with UC and 77 with CD. The utilization of biologic therapies saw a significant rise from 2020 to 2021, particularly with anti-TNF agents being the most frequently prescribed. The patterns observed in outpatient visits and hospital admissions followed similar trajectories, exhibiting a downturn during the COVID-19 pandemic.
Conclusions
This study examined the epidemiology, HCRU, and costs of IBD in Colombia using SISPRO data. Despite a decrease during the COVID-19 pandemic, the incidence and prevalence of IBD have increased over time, accompanied by elevated HCRU and medication costs. These insights could contribute to informed decision-making and resource allocation for enhanced patient care in Colombia.
背景和目的：炎症性肠病（IBD）的发病率和患病率，包括克罗恩病（CD）和溃疡性结肠炎（UC），在拉丁美洲正在增加。IBD对患者的生活质量有重要影响，并与显著的医疗资源利用率（HCRU）相关。本研究旨在描述哥伦比亚IBD的最新流行病学特征和HCRU模式。方法：回顾性研究使用国家索赔数据库SISPRO (Sistema de Información para la Protección Social) 2017年至2021年的真实数据。考虑的数据包括社会人口学（性别和年龄）、流行病学（发病率、患病率和死亡率）和HCRU数据。结果：我们确定了54,961例普遍溃疡性结肠炎（UC）和13,136例克罗恩病（CD）。在2017年至2019年期间，UC的发病率从每10万人3.82例上升到5.18例，而CD的发病率从每10万人0.48例上升到0.83例。这些疾病的患病率在2019年达到最高点，UC为每10万人48.65人，CD为15.41人。死亡率数据显示，UC登记的死亡人数为259人，CD登记的死亡人数为77人。从2020年到2021年，生物疗法的使用率显著上升，特别是抗肿瘤坏死因子药物是最常用的处方。在门诊就诊和住院中观察到的模式遵循类似的轨迹，在COVID-19大流行期间表现出低迷。结论：本研究使用SISPRO数据调查了哥伦比亚IBD的流行病学、HCRU和费用。尽管在2019冠状病毒病大流行期间有所下降，但随着时间的推移，IBD的发病率和流行率有所增加，同时HCRU和药物费用也有所上升。这些见解有助于在哥伦比亚作出明智的决策和分配资源，以加强对病人的护理。
{"title":"Epidemiology and healthcare resource utilization in inflammatory bowel disease in Colombia between 2017 and 2021: A retrospective claims database study","authors":"Fabián Juliao-Baños , Viviana Parra-Izquierdo , Tatiana Pacheco-Páez , Janeth Tatiana Acosta Leaño","doi":"10.1016/j.gastrohep.2025.502532","DOIUrl":"10.1016/j.gastrohep.2025.502532","url":null,"abstract":"<div><h3>Background and aims</h3><div>The incidence and prevalence of inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are increasing across Latin America. IBD has an important impact on patients’ quality of life and is associated with significant healthcare resource utilization (HCRU). This study aimed to describe the more recent epidemiological characteristics and HCRU patterns of IBD in Colombia.</div></div><div><h3>Methods</h3><div>Retrospective study using real-world data from the national claims database SISPRO (Sistema de Información para la Protección Social) between 2017 and 2021. The data considered were sociodemographic (sex and age), epidemiological (incidence, prevalence, and mortality), and HCRU data.</div></div><div><h3>Results</h3><div>We identified 54,961 cases of prevalent ulcerative colitis (UC) and 13,136 cases of Crohn's disease (CD). Between 2017 and 2019, the incidence rates for UC increased from 3.82 to 5.18 per 100,000 individuals, while the incidence for CD rose from 0.48 to 0.83 per 100,000. The prevalence of these conditions reached its highest point in 2019, with UC at 48.65 and CD at 15.41 per 100,000 population. Mortality data indicated 259 deaths registered with UC and 77 with CD. The utilization of biologic therapies saw a significant rise from 2020 to 2021, particularly with anti-TNF agents being the most frequently prescribed. The patterns observed in outpatient visits and hospital admissions followed similar trajectories, exhibiting a downturn during the COVID-19 pandemic.</div></div><div><h3>Conclusions</h3><div>This study examined the epidemiology, HCRU, and costs of IBD in Colombia using SISPRO data. Despite a decrease during the COVID-19 pandemic, the incidence and prevalence of IBD have increased over time, accompanied by elevated HCRU and medication costs. These insights could contribute to informed decision-making and resource allocation for enhanced patient care in Colombia.</div></div>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"49 1","pages":"Article 502532"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.gastrohep.2025.502527
Fermín Estremera-Arevalo , Silvia Bravo-Meléndez , Gonzalo Hijos-Mallada , Carlos Guarner-Argente , Marianette Murzi , Enrique Rodríguez-Santiago , Alberto Herreros de Tejada , Hugo Uchima-Koecklin , Pablo Miranda-García , David Barquero-Declara , Jose María Riesco-López , Pedro de María-Pallarés , Mª Gloria Fernández-Esparrach , Andrés Sánchez-Yagüe , Irene Aresté-Anduaga , Gonzalo Gonzalez-Gete , Carlos Teruel Sanchez-Vegazo , Beatriz Peñas-García , Sofía Parejo-Carbonell , Alba Martínez-Sánchez , Eduardo Albeniz
Objective
Peroral endoscopic myotomy (POEM) has emerged as a prominent endoscopic treatment for achalasia and other esophageal motility disorders (EMD). The objective of this study is to evaluate its clinical efficacy and safety after its implementation in Spain.
Patients and methods
This is a multicenter registry conducted across 13 hospitals in Spain. Symptomatic patients undergoing POEM for any EMD were recruited between June 2016 and February 2023. Baseline characteristics, procedural details and outcomes related to efficacy and safety during short and long-term follow-up were analyzed.
Results
A total of 441 patients were enrolled, with type II achalasia representing the most common diagnosis (62.1%). POEM was the primary treatment in 277 patients (62.8%). Clinical success data were available for 396 patients, with a success rate of 94.4% at the last available follow-up (2 years in 117 patients, 1 year in 140, <1 year in 139). A higher baseline Eckardt score was an independent risk factor for clinical failure in the long-term follow-up (p = 0.024). Symptomatic reflux occurred in 4.7% of the patients, with a significant esophagitis rate of 11.3%. Complication incidence was 9.3% (41/441), including 14 (3.2%) severe events. Older age (p = 0.025) and total procedure duration (p = 0.036) were independent risk factors for complications, while mucosal injury was found to be a predictor of severe complications (p = 0.027).
Conclusions
These findings confirm the clinical efficacy and safety during the implementation phase of POEM for all EMD in Spain.
{"title":"Clinical outcomes in the implementation of peroral endoscopic myotomy (POEM): Results from the Spanish multicenter registry","authors":"Fermín Estremera-Arevalo , Silvia Bravo-Meléndez , Gonzalo Hijos-Mallada , Carlos Guarner-Argente , Marianette Murzi , Enrique Rodríguez-Santiago , Alberto Herreros de Tejada , Hugo Uchima-Koecklin , Pablo Miranda-García , David Barquero-Declara , Jose María Riesco-López , Pedro de María-Pallarés , Mª Gloria Fernández-Esparrach , Andrés Sánchez-Yagüe , Irene Aresté-Anduaga , Gonzalo Gonzalez-Gete , Carlos Teruel Sanchez-Vegazo , Beatriz Peñas-García , Sofía Parejo-Carbonell , Alba Martínez-Sánchez , Eduardo Albeniz","doi":"10.1016/j.gastrohep.2025.502527","DOIUrl":"10.1016/j.gastrohep.2025.502527","url":null,"abstract":"<div><h3>Objective</h3><div>Peroral endoscopic myotomy (POEM) has emerged as a prominent endoscopic treatment for achalasia and other esophageal motility disorders (EMD). The objective of this study is to evaluate its clinical efficacy and safety after its implementation in Spain.</div></div><div><h3>Patients and methods</h3><div>This is a multicenter registry conducted across 13 hospitals in Spain. Symptomatic patients undergoing POEM for any EMD were recruited between June 2016 and February 2023. Baseline characteristics, procedural details and outcomes related to efficacy and safety during short and long-term follow-up were analyzed.</div></div><div><h3>Results</h3><div>A total of 441 patients were enrolled, with type II achalasia representing the most common diagnosis (62.1%). POEM was the primary treatment in 277 patients (62.8%). Clinical success data were available for 396 patients, with a success rate of 94.4% at the last available follow-up (2 years in 117 patients, 1 year in 140, <1 year in 139). A higher baseline Eckardt score was an independent risk factor for clinical failure in the long-term follow-up (<em>p</em> <!-->=<!--> <!-->0.024). Symptomatic reflux occurred in 4.7% of the patients, with a significant esophagitis rate of 11.3%. Complication incidence was 9.3% (41/441), including 14 (3.2%) severe events. Older age (<em>p</em> <!-->=<!--> <!-->0.025) and total procedure duration (<em>p</em> <!-->=<!--> <!-->0.036) were independent risk factors for complications, while mucosal injury was found to be a predictor of severe complications (<em>p</em> <!-->=<!--> <!-->0.027).</div></div><div><h3>Conclusions</h3><div>These findings confirm the clinical efficacy and safety during the implementation phase of POEM for all EMD in Spain.</div></div>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"49 1","pages":"Article 502527"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.gastrohep.2025.502576
Pilar Corsino Roche , Josep-Oriol Casanovas-Marsal , Santiago García López , Raquel Vicente Lidón , Eva Sierra Moros , Sonia Gallego Montañés , Diego Casas Deza , Laura Vicente Manso , Laura Lafarga-Molina
Objective
To translate, culturally adapt, and validate the Inflammatory Bowel Disease Knowledge questionnaire in adult Spanish-speaking patients with IBD.
Patients and methods
A cross-sectional translation and linguistic validation study was conducted with 30 participants aged > 18 years with Inflammatory Bowel Disease at the Miguel Servet University Hospital (Zaragoza, Spain). The IBD-KNOW questionnaire was translated and culturally adapted following ISPOR guidelines. Content validity was assessed by a panel of experts using Aiken's V coefficient. Internal consistency was evaluated using Cronbach's alpha, and test–retest reliability was assessed with the intraclass correlation coefficient (ICC). Descriptive analyses and bivariate tests were used to evaluate sociodemographic and clinical variables, as well as associations with IBD knowledge.
Results
The study assessed 30 adults (50% female) with an average age of 44.21 ± 15.05 years; mean age at diagnosis 29.24 ± 11.42 years and mean disease duration 14.97 ± 8.70 years. The Spanish version of the IBD-KNOW demonstrated good internal consistency (Cronbach's α = 0.74) and strong test–retest reliability (ICC = 0.80; 95% CI: 0.62–0.89). No statistically significant differences were found between the test and retest scores (p = 0.39) or completion times (p = 0.736). The mean questionnaire score was 5.87 ± 1.53 out of 10.
Conclusions
The Spanish version of the IBD-KNOW questionnaire is a valid, reliable, and culturally appropriate instrument for assessing disease-related knowledge in Spanish-speaking IBD patients. Its use in clinical settings can support the identification of educational needs and the design of targeted interventions aimed at improving patient engagement and health outcomes.
{"title":"Translation and psychometric evaluation of the Spanish version of the Inflammatory Bowel Disease Knowledge (IBD-KNOW) questionnaire","authors":"Pilar Corsino Roche , Josep-Oriol Casanovas-Marsal , Santiago García López , Raquel Vicente Lidón , Eva Sierra Moros , Sonia Gallego Montañés , Diego Casas Deza , Laura Vicente Manso , Laura Lafarga-Molina","doi":"10.1016/j.gastrohep.2025.502576","DOIUrl":"10.1016/j.gastrohep.2025.502576","url":null,"abstract":"<div><h3>Objective</h3><div>To translate, culturally adapt, and validate the Inflammatory Bowel Disease Knowledge questionnaire in adult Spanish-speaking patients with IBD.</div></div><div><h3>Patients and methods</h3><div>A cross-sectional translation and linguistic validation study was conducted with 30 participants aged<!--> <!-->><!--> <!-->18 years with Inflammatory Bowel Disease at the Miguel Servet University Hospital (Zaragoza, Spain). The IBD-KNOW questionnaire was translated and culturally adapted following ISPOR guidelines. Content validity was assessed by a panel of experts using Aiken's <em>V</em> coefficient. Internal consistency was evaluated using Cronbach's alpha, and test–retest reliability was assessed with the intraclass correlation coefficient (ICC). Descriptive analyses and bivariate tests were used to evaluate sociodemographic and clinical variables, as well as associations with IBD knowledge.</div></div><div><h3>Results</h3><div>The study assessed 30 adults (50% female) with an average age of 44.21<!--> <!-->±<!--> <!-->15.05 years; mean age at diagnosis 29.24<!--> <!-->±<!--> <!-->11.42 years and mean disease duration 14.97<!--> <!-->±<!--> <!-->8.70 years. The Spanish version of the IBD-KNOW demonstrated good internal consistency (Cronbach's <em>α</em> <!-->=<!--> <!-->0.74) and strong test–retest reliability (ICC<!--> <!-->=<!--> <!-->0.80; 95% CI: 0.62–0.89). No statistically significant differences were found between the test and retest scores (<em>p</em> <!-->=<!--> <!-->0.39) or completion times (<em>p</em> <!-->=<!--> <!-->0.736). The mean questionnaire score was 5.87<!--> <!-->±<!--> <!-->1.53 out of 10.</div></div><div><h3>Conclusions</h3><div>The Spanish version of the IBD-KNOW questionnaire is a valid, reliable, and culturally appropriate instrument for assessing disease-related knowledge in Spanish-speaking IBD patients. Its use in clinical settings can support the identification of educational needs and the design of targeted interventions aimed at improving patient engagement and health outcomes.</div></div>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"49 1","pages":"Article 502576"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.gastrohep.2025.502497
Sara Sánchez Moreno, Ana Plaza Fernández, Francisca Anguita Montes
{"title":"Divertículo duodenal intraluminal: una causa inusual de hemorragia digestiva alta","authors":"Sara Sánchez Moreno, Ana Plaza Fernández, Francisca Anguita Montes","doi":"10.1016/j.gastrohep.2025.502497","DOIUrl":"10.1016/j.gastrohep.2025.502497","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"49 1","pages":"Article 502497"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.gastrohep.2025.502534
Pablo Fernández Rodriguez , Lidia Castillo Gázquez , Tomás Álvarez Malé , Mirella Jiménez Gómez
{"title":"Distrofia quística duodenal con diagnóstico final de adenocarcinoma de páncreas: ¿relación directa o hallazgo casual?","authors":"Pablo Fernández Rodriguez , Lidia Castillo Gázquez , Tomás Álvarez Malé , Mirella Jiménez Gómez","doi":"10.1016/j.gastrohep.2025.502534","DOIUrl":"10.1016/j.gastrohep.2025.502534","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"49 1","pages":"Article 502534"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144811967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号